Drug discovery company LabGenius has closed a £35 million Series B financing round.  The investment brings total funding at London-based LabGenius, pioneering the use of machine learning for the discovery of novel therapeutic antibodies, to £58m. It will use the new funds to further develop its ML-driven drug discovery platform. The company will also progress … Continue reading £35m funding injection for AI drug discovery firm